Cargando…

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry

Detalles Bibliográficos
Autores principales:	Mato, Anthony R., Ghosh, Nilanjan, Sharman, Jeff P., Brander, Danielle, Gutierrez, Meghan, Huang, Qing, Wu, Linda H., Young, Alex, Upasani, Sandhya, Naganuma, Maoko, Barrientos, Jacqueline C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468359/ https://www.ncbi.nlm.nih.gov/pubmed/36206191 http://dx.doi.org/10.1182/bloodadvances.2022008068

Ejemplares similares

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
por: Mato, Anthony R., et al.
Publicado: (2019)

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
por: Kittai, Adam S., et al.
Publicado: (2022)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
por: Vassilopoulos, Stephanos, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology
por: Kastenbaum, Hannah A., et al.
Publicado: (2010)

Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region
por: Bott, Patricia, et al.
Publicado: (2022)

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL
por: Kadkol, Shrihari S., et al.
Publicado: (2021)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Bilateral breast implant associated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A case report
por: Bletsis, Patrick P., et al.
Publicado: (2020)

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
por: Brown, J R, et al.
Publicado: (2018)

Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non‐specific hypersensitivity reactions
por: Abbott, James, et al.
Publicado: (2023)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)
por: Sitlinger, Andrea, et al.
Publicado: (2021)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
por: Ito, Masato, et al.
Publicado: (2002)

Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study
por: Deering, Kathleen L., et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Microvesicles in CLL: predictor of disease progression/relapse
por: Maiti, Guru P., et al.
Publicado: (2017)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

CLL und Covid-19
por: Behrend, Christian
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vl225531cra9osak4ud8e43sdj